Roots Analysis

Roots Analysis has done a detailed study on Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Key Market Insights • Over 235 companies worldwide claim to offer contract manufacturing services for various types of biopharmaceutical drug / therapy products. • The market landscape is highly fragmented featuring the presence of both established players and new entrants; majority of biopharmaceutical CMOs are based in the developed geographies. • Case study: CMOs focusing on niche biologic markets, primarily novel product candidates for which in-house biomanufacturing expertise is low, are likely to experience significant growth in the coming years. • The installed global contract manufacturing capacity, spread across various geographies, is currently estimated to be over 4.5 million liters. • The demand for contract manufacturing services is expected to rise across different therapeutic areas; closer inspection of available capacity and expected utilization trend are required to optimize supply parameters. • With over 450 deals inked in the past six years, there has been a surge in the partnership activity; majority of the collaborations have been signed for the development and manufacturing of cell therapies and antibodies. • In order to cater the increasing demand for biologics, stake holders are actively expanding their existing capabilities; this is evident from the various acquisitions that have recently been reported. • We expect the developers to continue to outsource their manufacturing operations in the short to mid-term, resulting in an annualized growth rate of more than 8%. • In the long term, the projected opportunity is anticipated to be well distributed across various types of expression systems used for biomanufacturing, scale of operation and size of contract service providers Read Detailed Analysis: https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Table of Contents Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Context and Background 3.2. An Overview of Biopharmaceuticals 3.3. Biopharmaceutical Manufacturing 3.3.1. Types of Expression Systems 3.3.1.1. Bacterial Expression Systems 3.3.1.2. Yeast Expression Systems 3.3.1.3. Fungal Expression Systems 3.3.1.4. Insect Expression Systems 3.3.1.5. Plant Expression Systems 3.3.1.6. Mammalian Expression Systems 3.3.2. Manufacturing Steps 3.3.2.1. Upstream Processing 3.3.2.2. Downstream Processing 3.4. An Overview of Contract Manufacturing 3.5. Need for Outsourcing in the Biopharmaceutical Industry 3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry 3.7. Basic Guidelines for Selecting a CMO Partner 3.8. Advantages of Outsourcing Manufacturing Services 3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing 3.10. Concluding Remarks 4. COMPETITIVE LANDSCAPE 4.1. Chapter Overview 4.2. Biopharmaceuticals Contract Manufacturers: Overall Market Landscape 4.2.1. Analysis by Size of Employee Base 4.2.2. Analysis by Location of Headquarters 4.2.3. Analysis by Year of Establishment 4.2.4. Analysis by Location of Manufacturing Facilities 4.2.5. Analysis by Type of Biologics Manufactured 4.2.6. Analysis by Scale of Operation 4.2.7. Analysis by Expression Systems 4.2.8. Analysis by Type of Bioreactor and Modes of Operation 4.2.9. Analysis by Biomanufacturing Capacity 4.2.10. Analysis by Packaging Form 4.3. Concluding Remarks 5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA 5.1. Chapter Overview 5.2. Biopharmaceutical Outsourcing in the US: Regulatory Scenario 5.2.1. Impact of Current Political Situation 5.3. Leading Biopharma CMOs in North America 5.3.1. AMRI (OsoBio) 5.3.1.1. Company Overview 5.3.1.2. Services Portfolio 5.3.1.3. Financial Information 5.3.1.4. Manufacturing Facilities 5.3.1.5. Partnerships 5.3.1.6. Recent Developments 5.3.1.7. Future Outlook 5.3.2. Baxter BioPharma Solutions 5.3.2.1. Company Overview 5.3.2.2. Services Portfolio 5.3.2.3. Financial Information 5.3.2.4. Manufacturing Facilities 5.3.2.5. Partnerships 5.3.2.6. Recent Developments 5.3.2.7. Future Outlook 5.3.3. Catalent Biologics (Catalent Pharma Solutions) 5.3.3.1. Company Overview 5.3.3.2. Services Portfolio 5.3.3.3. Financial Information 5.3.3.4. Manufacturing Facilities 5.3.3.5. Partnerships 5.3.3.6. Recent Developments 5.3.3.7. Future Outlook 5.3.4. Cytovance Biologics 5.3.4.1. Company Overview 5.3.4.2. Services Portfolio 5.3.4.3. Partnerships 5.3.4.4. Recent Developments 5.3.4.5. Future Outlook 5.3.5. Patheon 5.3.5.1. Company Overview 5.3.5.2. Services Portfolio 5.3.5.3. Financial Information 5.3.5.4. Manufacturing Facilities 5.3.5.5. Partnerships 5.3.5.6. Recent Developments 5.3.5.7. Future Outlook 5.3.6. Piramal Pharma Solutions 5.3.6.1. Company Overview 5.3.6.2. Services Portfolio 5.3.6.3. Financial Information 5.3.6.4. Facilities 5.3.6.5. Partnerships 5.3.6.6. Recent Developments 5.3.6.7. Future Outlook 6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE 6.1. Chapter Overview 6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario 6.3. Leading Biopharmaceutical CMOs in Europe 6.3.1. 3P Biopharmaceuticals 6.3.1.1. Company Overview 6.3.1.2. Services Portfolio 6.3.1.3. Manufacturing Facilities 6.3.1.4. Partnerships 6.3.1.5. Recent Developments 6.3.1.6. Future Outlook 6.3.2. Boehringer Ingelheim BioXcellence™ 6.3.2.1. Company Overview 6.3.2.2. Services Portfolio 6.3.2.3. Financial Information 6.3.2.4. Manufacturing Facilities 6.3.2.5. Partnerships 6.3.2.6. Recent Developments 6.3.2.7. Future Outlook 6.3.3. Celonic 6.3.3.1. Company Overview 6.3.3.2. Services Portfolio 6.3.3.3. Manufacturing Facilities 6.3.3.4. Partnerships 6.3.3.5. Recent Developments 6.3.3.6. Future Outlook 6.3.4. FUJIFILM Diosynth Biotechnologies 6.3.4.1. Company Overview 6.3.4.2. Services Portfolio 6.3.4.3. Financial Information 6.3.4.4. Manufacturing Capabilities 6.3.4.5. Partnerships 6.3.4.6. Recent Developments 6.3.4.7. Future Outlook 6.3.5. LFB Group 6.3.5.1. Company Overview 6.3.5.2. Services Portfolio 6.3.5.3. Financial Information 6.3.5.4. Manufacturing Facilities 6.3.5.5. Partnerships 6.3.5.6. Recent Developments 6.3.5.7. Future Outlook 6.3.6. Lonza 6.3.6.1. Company Overview 6.3.6.2. Services Portfolio 6.3.6.3. Financial Information 6.3.6.4. Manufacturing Facilities 6.3.6.5. Partnerships 6.3.6.6. Recent Developments 6.3.6.7. Future Outlook 6.3.7. Menarini Biotech 6.3.7.1. Company Overview 6.3.7.2. Services Portfolio 6.3.7.3. Partnerships 6.3.7.4. Future Outlook 6.3.8. Novasep 6.3.8.1. Company Overview 6.3.8.2. Services Portfolio 6.3.8.3. Financial Information 6.3.8.4. Partnerships 6.3.8.5. Recent Developments 6.3.8.6. Future Outlook 6.3.9. Rentschler BioPharma 6.3.9.1. Company Overview 6.3.9.2. Services Portfolio 6.3.9.3. Manufacturing Facilities 6.3.9.4. Partnerships 6.3.9.5. Recent Developments 6.3.9.6. Future Outlook 7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA PACIFIC AND THE REST OF THE WORLD 7.1. Chapter Overview 7.2. Biopharmaceutical Contract Manufacturing in China 7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario 7.2.2. Challenges Faced while Outsourcing to China 7.3. Biopharmaceutical CMOs in China 7.3.1. AutekBio 7.3.1.1. Company Overview 7.3.1.2. Services Portfolio 7.3.1.3. Manufacturing Facilities 7.3.1.4. Future Outlook 7.3.2. WuXi AppTec (WuXi Biologics) 7.3.2.1. Company Overview 7.3.2.2. Services Portfolio 7.3.2.3. Financial Information 7.3.2.4. Manufacturing Facilities 7.3.2.5. Partnerships 7.3.2.6. Recent Developments 7.3.2.7. Future Outlook 7.4. Biopharmaceutical Contract Manufacturing in India 7.4.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario 7.4.2. Challenges Faced while Outsourcing to India 7.5. Biopharmaceutical CMOs in India 7.5.1. Intas Pharmaceuticals 7.5.1.1. Company Overview 7.5.1.2. Services Portfolio 7.5.1.3. Financial Information 7.5.1.4. Manufacturing Facilities 7.5.1.5. Future Outlook 7.5.2. Kemwell Biopharma 7.5.2.1. Company Overview 7.5.2.2. Services Portfolio 7.5.2.3. Manufacturing Facilities 7.5.2.4. Partnerships 7.5.2.5. Recent Developments 7.5.2.6. Future Outlook 7.5.3. Shasun Pharmaceuticals 7.5.3.1. Company Overview 7.5.3.2. Services Portfolio 7.5.3.3. Financial Information 7.5.3.4. Future Outlook 7.5.4. Syngene 7.5.5.1. Company Overview 7.5.5.2. Services Portfolio 7.5.5.3. Financial Information 7.5.5.4. Manufacturing Facilities 7.5.5.5. Partnerships 7.5.5.6. Recent Developments 7.5.5.7. Future Outlook 7.6. Biopharmaceutical Contract Manufacturing in Japan 7.6.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario 7.7. Biopharmaceutical CMOs in Japan 7.6.1. Asahi Glass 7.6.1.1. Company Overview 7.6.1.2. Services Portfolio 7.6.1.3. Financial Information 7.6.1.4. Manufacturing Facilities 7.6.1.5. Partnerships 7.7.1.6. Recent Developments 7.7.1.7. Future Outlook 7.8. Biopharmaceutical Contract Manufacturing in South Korea 7.7.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario 7.7. Biopharmaceutical CMOs in South Korea 7.7.1. DM Bio 7.7.1.1. Company Overview 7.7.1.2. Services Portfolio 7.7.1.3. Manufacturing Facilities 7.7.1.4. Future Outlook 7.7.2. Samsung BioLogics 7.7.2.1. Company Overview 7.7.2.2. Services Portfolio 7.7.2.3. Financial Information 7.7.2.4. Manufacturing Facilities 7.7.2.5. Partnerships 7.7.2.6. Recent Developments 7.7.2.7. Future Outlook 7.9. Biopharmaceutical Contract Manufacturing in Australia 7.8.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario 7.8. Biopharmaceutical CMOs in Australia 7.8.2. Cell Therapies 7.8.2.1. Company Overview 7.8.2.2. Services Portfolio 7.8.2.3. Manufacturing Facilities 7.8.2.4. Partnerships 7.8.2.5. Recent Developments 7.8.2.6. Future Outlook 7.8.3. Luina Bio 7.8.3.1. Company Overview 7.8.3.2. Services Portfolio 7.8.3.3. Manufacturing Facilities 7.8.3.4. Partnerships 7.8.3.5. Future Outlook 8. NICHE BIOPHARMACEUTICAL SECTORS 8.1. Chapter Overview 8.2. Antibody Drug Conjugates 8.2.1. Introduction 8.2.1.1. Manufacturing Process 8.2.1.2. Key Technologies and Technology Providers 8.2.2. Pipeline Analysis 8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules 8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules 8.2.2.3. ADC Manufacturing: Key Challenges 8.3. Bispecific Antibodies 8.3.1. Introduction 8.3.1.1. The Bispecific Advantage 8.3.2. Pipeline Analysis 8.3.3. Bispecific Antibody Technology Providers 8.3.4. Contract Manufacturing Scenario 8.4. Cell Therapies 8.4.1. Introduction 8.4.2. Current Market Landscape 8.4.3. Cell Therapy Manufacturing 8.4.4. Cell Therapy Manufacturing Models 8.4.4.1. Centralized Manufacturing Model 8.4.4.2. Decentralized Manufacturing Model 8.4.5. Cell Therapy Manufacturing: Key Challenges and Growth Drivers 8.4.6. Important Factors for Cell Therapy Manufacturing 8.4.6.1. Cell Characterization 8.4.6.2. Cost of Goods 8.4.7. Contract Manufacturing Scenario 8.4.7.1. Analysis by Type of Cells Manufactured 8.4.7.2. Analysis by Scale of Operation 8.5. Gene Therapy 8.5.1. Introduction 8.5.2. Gene Therapy: Pipeline Analysis 8.5.2.1. Analysis by Phase of Development 8.5.2.2. Analysis by Type of Vector 8.5.2.3. Analysis by Therapeutic Area 8.5.3. Contract Manufacturing Market Landscape 8.5.3.1. Analysis by Location 8.5.3.2. Analysis by Type of Viral Vector 8.5.3.3. Analysis by Scale of Production 8.6. Plasmid DNA 8.6.1. Introduction 8.6.2. Contract Manufacturing Market Landscape 8.6.3. Analysis by Location of Manufacturing Facility 8.6.4. Analysis by Scale of Production 9. CASE STUDY: OUTSOURCING OF BIOSIMILARS 9.1. Chapter Overview 9.2. Biosimilars: An Introduction 9.3. Biosimilars: Development Stages 9.4. Regulatory Requirements for Licensing of Biosimilars 9.5. Need for Outsourcing Biosimilar Development and Manufacturing 9.6. Impact of Biosimilars on the Global Contract Manufacturing Market 9.6.1. Region-wise Distribution of Biosimilar Development / Manufacturing Activity 9.7. List of Biosimilars Contract Manufacturing Service Provider 9.8. Challenges Associated with Biosimilar Outsourcing 10. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES 10.1. Chapter Overview 10.2. Small Molecule and Large Molecule Drugs / Therapies 10.2.1. Comparison of General Characteristics 10.2.2. Comparison of Key Specifications 10.2.3. Comparison of Manufacturing Processes 10.2.4. Comparison of Key Manufacturing Challenges 11. CASE STUDY ON IN-HOUSE MANUFACTURING 11.1. Chapter Overview 11.2. In-House Manufacturing 11.2.1. Benefits Associated with In-House Manufacturing 11.2.2. Risks Associated with In-House Manufacturing 11.3. Outsourcing in the Biomanufacturing Industry 11.3.1. Types of Outsourcing Partners 11.4. Manufacturing Approaches Used for Approved Biologics (2016-2018) 11.4.1. Approved Biologics: Distribution by Size of Type of Manufacturing Approach 11.4.2. Approved Biologics: Distribution by Size of Developer and Type of Biologic 11.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing 12. COLLABORATIONS 12.1. Chapter Overview 12.2. Partnership Models 12.3. Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations 12.3.1. Analysis by Year of Partnerships 12.3.2. Analysis by Type of Partnerships 12.3.2.1. Year-Wise Trend of Product-based Agreements 12.3.2.2. Year-Wise Trend of Process-based Agreements 12.3.2.3. Year-Wise Trend of Licensing Agreements 12.3.2.4. Year-Wise Trend of Co-service Agreements / Ventures 12.3.2.5. Year-Wise Trend of R&D Agreements 12.3.2.6. Year-Wise Trend of Out-sourcing Services Agreements 12.3.3. Analysis by Focus Area 12.3.4. Analysis by Type of Biologics 12.3.4.1. Analysis by Type of Biologic and Type of Partnership Model 12.3.4.2. Analysis of Cell Therapy-related Deals by Year and Type of Partnership Model 12.3.4.3. Analysis of Monoclonal Antibody-related Deals by Year and Type of Partnership Model 12.3.4.4. Analysis of Vaccine-related Deals by Year and Type of Partnership Model 12.3.4.5. Analysis of Protein-related Deals by Year and Type of Partnership Model 12.3.4.6. Analysis of Antibody Drug Deals by Year and Type of Partnership Model 12.3.4.7. Analysis of Vector-related Deals by Year and Type of Partnership Model 12.3.4.8. Analysis of Gene Therapy-related Deals by Year and Type of Partnership Model 12.3.4.9. Analysis of Biosimilar-related Deals by Year and Type of Partnership Model 12.3.4.10. Analysis of Other Biologic-related Deals by Type of Partnership Model 12.3.4.11. Analysis by Type of Biologics and Geography 12.3.5. Analysis by Therapeutic Area 12.3.6. Analysis of Most Active Players by Number of Partnerships 12.3.7. Regional Analysis 12.3.7.1. Intercontinental and Intracontinental Agreements 12.4. Mergers and Acquisitions 12.4.1. Acquisitions Models 12.4.2. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions 12.4.3. Cumulative Year-wise Trend 12.4.4. Analysis by Type of Acquisition 12.4.5. Geographical Activity 12.4.5.1. Mergers and Acquisitions: Continent-wise Distribution 12.4.5.2. Mergers and Acquisitions: Country-wise Distribution 12.4.5.3. Mergers and Acquisitions: Intercontinental and Intracontinental Deals 12.4.6. Most Active Acquirers: Analysis by Number of Acquisitions 12.4.7 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologics 12.4.7.1. Mergers and Acquisitions: Analysis by Key Value Drivers 12.4.7.2. Mergers and Acquisitions: Analysis by Key Value Drivers and Year of Acquisition 12.4.7.3. Mergers and Acquisitions: Analysis by Type of Biologics 12.4.7.4. Mergers and Acquisitions: Analysis by Type of Biologics and Key Value Drivers 12.5. Key Acquisitions: Deal Multiples 13. RECENT DEVELOPMENTS 13.1. Chapter Overview 13.2. Biopharma Contract Manufacturing Market: Facility Expansions 13.2.1. Cumulative Year-wise Distribution 13.2.2. Analysis by Purpose of Facility Expansion 13.2.3. Analysis by Type of Biologics 13.2.4. Analysis by Type of Biologics and Purpose of Expansion 13.2.5. Analysis by Location of Manufacturing Facility 13.2.6. Regional Analysis 13.2.7. Most Active Players: Analysis by Number of Recent Expansions 13.2.8. Analysis by Headquarters and Purpose 13.2.9. Facility Expansions: Pre-2015 and Post-2015 13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances 13.4. Technological Advancements 13.4.1. Single Use Technology 13.4.2. Process Analytical Technology (PAT) 13.4.3. Continuous Processing 13.4.4. Quality by Design in Bioprocessing 13.3. Biopharmaceutical Contract Manufacturing Market: Funding Instances 13.5. Technological Advancements 13.4.1. Single Use Technology 13.4.2. Process Analytical Technology 13.4.3. Continuous Processing 13.4.4. Quality by Design in Bioprocessing 14. CAPACITY ANALYSIS 14.1. Chapter Overview 14.2. Assumptions and Methodology 14.3. Biopharmaceutical Contract Manufacturers: Global Production Capacity 14.3.1. Analysis by Size of the CMO 14.3.2. Analysis by Expression Systems 14.3.3. Analysis by Scale of Operation 14.3.4. Analysis by Region 14.3.4.1. Capacity Analysis: North America 14.3.4.2. Capacity Analysis: Europe 14.3.4.3. Capacity Analysis: Asia and Middle East 14.4. Emerging Biologics: Capacity Analysis 14.4.1. ADC Manufacturing Installed Global Capacity: Regional Distribution 14.5. Cell Therapy Manufacturing Capacity: Regional Distribution 14.6. Viral Vectors Installed Manufacturer Capacity: Distribution by Location of Manufacturing Facility 14.7. Concluding Remarks DEMAND ANALYSIS 14.8. Chapter Overview 14.9. Key Assumptions and Methodology 14.10. Overall Annual Demand for Biopharmaceutical Market, 2019-2024 14.10.1. Analysis by Therapeutic Area 14.11. Relationship Between Annual Demand and Capacity 14.12. Demand for Emerging Novel Biologics 14.12.1. ADCs: Overall Annual Demand 15. MARKET FORECAST 15.1. Chapter Overview 15.2. Forecast Methodology and Key Assumptions 15.3. Overall Biopharmaceutical Contract Manufacturing Market, 2019-2030 15.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2019-2030 15.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2019-2030 15.4. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Expression Systems Used 15.5. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation 15.6. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Size of Manufacturers 15.7. Biopharmaceutical Contract Manufacturing Market, 2019-2030: Distribution by Geography 15.7.1. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030 15.7.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2019-2030 15.7.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2019-2030 15.7.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mammalian Cell-based Operations 15.7.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Microbial Cell-based Operations 15.7.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Other Expression System-based Operations 15.7.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Preclinical / Clinical Scale Operations 15.7.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Commercial Scale Operations 15.7.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Small-sized Companies 15.7.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Mid-sized Companies 15.7.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2019-2030: Share of Large / Very Large Companies 15.7.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030 15.7.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2019-2030 15.7.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2019-2030 15.7.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2019-2030 15.7.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2019-2030 15.7.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2019-2030 15.7.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2019-2030 15.7.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mammalian Cell-based Operations 15.7.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Microbial Cell-based Operations 15.7.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Other Expression System-based Operations 15.7.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Preclinical / Clinical Operations 15.7.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Commercial Operations 15.7.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Small-sized Companies 15.7.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Mid-sized Companies 15.7.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2019-2030: Share of Large / Very Large Companies 15.7.3. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 15.7.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2019-2030 15.7.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2019-2030 15.7.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2019-2030 15.7.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2019-2030 15.7.3.5. Biopharmaceutical Contract Manufacturing Market in Australia, 2019-2030 15.7.3.6. Biopharmaceutical Contract Manufacturing Market in Rest of Asia and Other Regions, 2019-2030 15.7.3.7. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mammalian Cell-based Operations 15.7.3.8. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Microbial Cell-based Operations 15.7.3.9. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Other Expression System-based Operations 15.7.3.10. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Preclinical / Clinical Operations 15.7.3.11. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Commercial Scale Operations 15.7.3.12. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Small-sized Companies 15.7.3.13. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Share of Mid-sized Companies 15.7.3.14. Biopharmaceutical Contract Manufacturing Market in Asia and Rest of the World, 2019-2030: Large / Very Large Companies 16.7.4 Overall Biopharmaceutical Contract Manufacturing, 2019-2030: Share by Others Segment 16. SWOT ANALYSIS 17.1 Chapter Overview 17.2. Strengths 17.3. Weaknesses 17.4. Opportunities 17.5. Threats 17.6. Comparison of Swot Factors 17.7. Concluding Remarks 17. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET 17.1. Chapter Overview 17.2. Outsourcing Activities to Witness Significant Growth in the Coming Years 17.3. Shift from One-time Contracts to Strategic Partnerships 17.4. Integration / Adoption of New and Innovative Technologies 17.4.1. Single use Bioreactors 17.4.2. Novel Bioprocess Techniques 17.4.3. Bioprocess Automation 17.5. Focus on Niche Therapeutic Areas 17.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment 17.7. Capability and Expertise Expansions by CMOs to become One Stop Shops 17.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities 17.9. Increase in Financial Inflow and Outsourcing Budgets 17.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies 17.11. Challenges Faced by both Sponsors and Service Providers 17.11.1. Concerns related to Single Use Systems 17.11.2. Issues Related to Capacity Fluctuations 17.12. Concluding Remarks 18. SURVEY ANALYSIS 18.1. Chapter Overview 18.1.1. Overview of Respondents 18.1.2. Designation of Respondents 18.2. Biologics Manufacturing Expertise 18.3. Scale of Manufacturing 18.4. Location of Production Facilities 18.5. Types of Expression Systems Used 18.6. Types of Bioreactors 18.7. Modes of Operation of Bioreactors 19. INTERVIEW TRANSCRIPTS 19.1. Chapter Overview 19.2. Astrid Brammer, Senior Manager Business Development, Richter-Helm 19.3. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie 19.4. Christian Bailly, Director of CDMO, Pierre Fabre 19.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences 19.6. David C Cunningham, Director Corporate Development, Goodwin Biotechnology 19.7. Dietmar Katinger, Chief Executive Officer, Polymun Scientific 19.8. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma 19.9. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences 19.10. Kevin Daley, Director Pharmaceuticals, Novasep 19.11. Mark Wright, Site Head, Grangemouth, Piramal Healthcare 19.12. Nicolas Grandchamp, R&D Leader, GEG Tech 19.13. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals 19.14. Sebastian Schuck, Head of Business Development, Wacker Biotech 19.15. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies 19.16. Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, Plasmid Factory 19.17. Tim Oldham, Chief Executive Officer, Cell Therapies 20. APPENDIX 1: LIST OF NON-INDUSTRY PLAYERS 21. APPENDIX 2: TABULATED DATA 22. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS For more information, please click on the following link: https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 Gaurav.Chaudhary@rootsanalysis.com